349 related articles for article (PubMed ID: 29669745)
1. GPR119 Agonism Increases Glucagon Secretion During Insulin-Induced Hypoglycemia.
Li NX; Brown S; Kowalski T; Wu M; Yang L; Dai G; Petrov A; Ding Y; Dlugos T; Wood HB; Wang L; Erion M; Sherwin R; Kelley DE
Diabetes; 2018 Jul; 67(7):1401-1413. PubMed ID: 29669745
[TBL] [Abstract][Full Text] [Related]
2. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
[TBL] [Abstract][Full Text] [Related]
3. β-Cell Inactivation of
Panaro BL; Flock GB; Campbell JE; Beaudry JL; Cao X; Drucker DJ
Diabetes; 2017 Jun; 66(6):1626-1635. PubMed ID: 28254842
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.
McKillop AM; Moran BM; Abdel-Wahab YH; Gormley NM; Flatt PR
Diabetologia; 2016 Dec; 59(12):2674-2685. PubMed ID: 27677765
[TBL] [Abstract][Full Text] [Related]
5. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
[TBL] [Abstract][Full Text] [Related]
6. A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression.
Kim MK; Cheong YH; Lee SH; Kim TH; Jung IH; Chae Y; Lee JH; Yang EK; Park H; Yang JS; Hong KW
Biomed Pharmacother; 2021 Dec; 144():112324. PubMed ID: 34678732
[TBL] [Abstract][Full Text] [Related]
7. Angelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119.
Park EY; Kim EH; Kim CY; Kim MH; Choung JS; Oh YS; Moon HS; Jun HS
PLoS One; 2016; 11(7):e0158796. PubMed ID: 27391814
[TBL] [Abstract][Full Text] [Related]
8. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
9. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
[TBL] [Abstract][Full Text] [Related]
10. Effects of insulin treatment without and with recurrent hypoglycemia on hypoglycemic counterregulation and adrenal catecholamine-synthesizing enzymes in diabetic rats.
Inouye KE; Yue JT; Chan O; Kim T; Akirav EM; Park E; Riddell MC; Burdett E; Matthews SG; Vranic M
Endocrinology; 2006 Apr; 147(4):1860-70. PubMed ID: 16396986
[TBL] [Abstract][Full Text] [Related]
11. Effects of alpha 2- and beta-adrenergic agonism on glucagon secretion from perfused pancreata of normal and streptozocin-induced diabetic rats.
Hirose H; Maruyama H; Ito K; Kido K; Koyama K; Saruta T
Metabolism; 1993 Aug; 42(8):1072-6. PubMed ID: 8102194
[TBL] [Abstract][Full Text] [Related]
12. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
[TBL] [Abstract][Full Text] [Related]
13. Regulation of glucagon secretion at low glucose concentrations: evidence for adenosine triphosphate-sensitive potassium channel involvement.
Muñoz A; Hu M; Hussain K; Bryan J; Aguilar-Bryan L; Rajan AS
Endocrinology; 2005 Dec; 146(12):5514-21. PubMed ID: 16123162
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
15. Regulation of alpha-cell function by the beta-cell during hypoglycemia in Wistar rats: the "switch-off" hypothesis.
Zhou H; Tran PO; Yang S; Zhang T; LeRoy E; Oseid E; Robertson RP
Diabetes; 2004 Jun; 53(6):1482-7. PubMed ID: 15161752
[TBL] [Abstract][Full Text] [Related]
16. High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice.
Zhang M; Feng Y; Wang J; Zhao J; Li T; He M; Yang D; Nosjean O; Boutin J; Renard P; Wang MW
PLoS One; 2013; 8(5):e63861. PubMed ID: 23704946
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal hormonal responses on GPR119 activation in lean and diseased rodent models of type 2 diabetes.
Patel S; Mace OJ; Tough IR; White J; Cock TA; Warpman Berglund U; Schindler M; Cox HM
Int J Obes (Lond); 2014 Oct; 38(10):1365-73. PubMed ID: 24451185
[TBL] [Abstract][Full Text] [Related]
19. Metabolic disturbances and defects in insulin secretion in rats with streptozotocin-nicotinamide-induced diabetes.
Szkudelski T; Zywert A; Szkudelska K
Physiol Res; 2013; 62(6):663-70. PubMed ID: 23869889
[TBL] [Abstract][Full Text] [Related]
20. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
Li H; Fang Y; Guo S; Yang Z
Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
[No Abstract] [Full Text] [Related]
[Next] [New Search]
